Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 17/20 | 0.41 |
| ▸ | KDM4A | O75164 | 12/20 | 0.41 |
| ▸ | KDM5A | P29375 | 6/20 | 0.41 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31369528 | 0.94 | ALDH1A1 (0.47) | ALDH1A1CHRNB2CHRNB4CHRNA4KDM4C | |
| SCHEMBL22915367 | 0.88 | ALDH1A1 (0.41) | ALDH1A1CHRNB2CHRNB4CHRNA4KDM4C | |
| SCHEMBL288365 | 0.80 | LMNA (0.53) | — | |
| SCHEMBL11113527 | 0.78 | LMNA (0.50) | — | |
| SCHEMBL812501 | 0.78 | ALDH1A1 (0.61) | ALDH1A1CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL6688889 | 0.78 | ALDH1A1 (0.61) | ALDH1A1CHRNB2CHRNB4CHRNA4PHF8 | |
| SCHEMBL4815884 | 0.76 | TSHR (0.60) | ALDH1A1KDM4CKDM4AKDM5AKDM7A | |
| SCHEMBL21703159 | 0.76 | TSHR (0.60) | ALDH1A1KDM4CKDM4AKDM5AKDM7A | |
| SCHEMBL20993533 | 0.76 | TSHR (0.60) | ALDH1A1KDM4CKDM4AKDM5AKDM7A | |
| SCHEMBL3293381 | 0.75 | ALDH1A1 (0.52) | ALDH1A1CHRNB2CHRNB4CHRNA4KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ALDH1A1 4838/4885CHRNB2 4812/4885CHRNB4 4743/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | ALDH1A1 4861/4885CHRNB2 4601/4885CHRNB4 4355/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | ALDH1A1 4472/4885CHRNB2 4641/4885CHRNB4 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.